Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)

Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation at General Session II and Award Ceremony I

Poster presentation to describe the antiviral activity of IRIG in HBV clinical isolates consisting of nucleoside/CpAM-resistant variants

HOPKINTON, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the acceptance of a late breaker oral presentation and a poster presentation at The International Liver Congress™ (ICL), the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14, 2019.

The late-breaker oral presentation by Professor Man-Fung Yuen, Chief of Gastroenterology and Hepatology, University of Hong Kong, and Principal Investigator of the ACHIEVE trial, scheduled for General Session II and Award Ceremony I, will describe the final top-line results from all inarigivir (IRIG) ACHIEVE trial cohorts, including the 200mg dosing cohort. As mentioned in the preliminary abstract published by the ICL yesterday, the full ACHIEVE trial and the IRIG 200mg dosing cohort met the primary endpoints of safety and HBV DNA reduction at week 12 after IRIG monotherapy. Spring Bank observed a dose-dependent response in HBV DNA reduction in both HBeAg-positive and HBeAg-negative patients with a maximal reduction of 3.26 log10. The full data on secondary virological endpoints, including HBV RNA, HBsAg and HBcrAg for all patients, was not available for the published preliminary abstract, but will be presented for the full 24-week treatment period by the principal investigator of the ACHIEVE trial at the ICL. This information remains subject to the ICL embargo policy and will be made available at the time of presentation.

Professor Stephen Locarnini, Head of Research & Molecular Development at the Victorian Infectious Diseases Reference Laboratory and Principal Investigator of the Virology Core for the ACHIEVE trial, will present the poster describing the antiviral activity of IRIG in HBV clinical isolates consisting of capsid inhibitor (CpAM) and nucleoside analog resistant variants. This data indicates that IRIG could be used as rescue or combination therapy for nucleoside/CpAM-resistant failures.

Presentation Details:

Oral Presentation        
Reference:   GS-12
Session:   General Session II and Award Ceremony I
Title:   Ascending dose cohort study of inarigivir – A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial
Date/Time:   Friday, April 12, 2019 at 10:15 a.m. CET
Presenter:   Prof. Man-Fung Yuen, University of Hong Kong
     
Poster Presentation    
Reference:   FRI-194
Session:   Viral hepatitis B/D: Therapy
Title:   The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid inhibitor resistant HBV in vitro
Date/Time:   Friday, April 12, 2019 from 9:00 a.m. to 5:00 p.m. CET
Presenter:   Prof. Stephen Locarnini, Victoria Infectious Diseases Reference Laboratory
     

Additional details, including presentation abstracts, can be found on the ILC website at https://ilc-congress.eu/. A copy of the presentation materials will be accessible by visiting the Presentations and Publications section of the Spring Bank Pharmaceuticals website after the presentations conclude.

About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company’s lead product candidate, inarigivir, is being developed for the treatment of chronic hepatitis B virus (HBV). Inarigivir is designed to activate within hepatic cells retinoic acid-inducible gene 1 (RIG-I), which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense. The company is also developing its lead STING agonist product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers. For more information, please visit www.springbankpharm.com.

Forward-Looking Statements
Statements in this press release about Spring Bank's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s preliminary data from the ACHIEVE trial inarigivir 200mg dosing cohort.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary data reported by Spring Bank changes following a more comprehensive review of the data related to the clinical trial and as more patient data become available or as additional analyses are conducted; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Spring Bank's Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on March 11, 2019 and in other filings Spring Bank makes with the SEC from time to time.

In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.

Contacts
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993

LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
Ashley@lifesciadvisors.com

Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank logo.png

Source: Spring Bank Pharmaceuticals, Inc.